Ranitidine Litigation Opens With Settlements, But Still Massive With State And MDL Trials Pending
Executive Summary
GSK and Sanofi will continue to defend against all claims alleging ranitidine increased risk of cancer. Four Rx generic firms reach settlements in first case scheduled for trial. Former US OTC Zantac marketers GSK and Sanofi, which markets the Zantac OTC brand in the US, along with former Rx brand marketer Pfizer could pay $1bn to $2bn each in potential settlements, analyst predicts.
You may also be interested in...
Ranitidine Cancer Risk Found Only By Litigation Plaintiffs’ ‘Unreliable’ Research, Judge Rules
Plaintiffs in Multi-District Litigation didn’t provide scientific evidence of OTC heartburn drug Zantac increasing risk of cancer. Federal judge says plaintiffs' research showed “a lack of substantiation for analytical leaps” in alleging dangerously high levels of NDMA in ranitidine drugs.
Euro Q3 Consumer Health Earnings Preview: Helm Changes, Investor Questions, Results Debut
Major Europe-based consumer health players Reckitt, Bayer, Sanofi and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2022 results over the coming weeks.
Big Pharmas Trust To The Science In Zantac Lawsuits
Billions of dollars have been wiped off the value of big pharma stocks as the market finally woke up to widescale litigation concerning allegations of increased cancer risk associated with the use of ranitidine. Two companies, GSK and Sanofi, are confident that there is no link.